Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 633 participants.

Also called NCT06327815

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 633 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06327815
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06327815. Randomized; no masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2025-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets
Intervention (Drug)
Dapagliflozin tablets and Metformin HCl extended-release tablets
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06327815
Content hash
83919b89fba902b5847b4ab8ea6bcb330cfdc394327e99dd0e52d814aea6b217